Randomized Study of AMPK Charge Dietary Supplement With or Without Semaglutide Injection to Improve Blood Sugar Control in Adults With Prediabetes or Type 2 Diabetes

What this Trial Is About

Researchers are evaluating the safety and effectiveness of AMPK Chargeae, a dietary supplement, alone and combined with semaglutide injections, in adults with prediabetes or Type 2 Diabetes. This randomized, single-blind, controlled trial aims to compare changes in fasting blood glucose, fasting insulin, and hemoglobin A1c HbA1c after 84 days of treatment with these two approaches. Participants will take AMPK Chargeae twice daily on an empty stomach, holding it in the mouth before swallowing. Some participants will also receive weekly subcutaneous injections of semaglutide, starting at 0.25 mg for four weeks, then increasing to 0.5 mg for the rest of the 84-day period. The study compares these two groups to assess differences in blood sugar control. During the study, participants will undergo regular assessments of blood glucose, insulin levels, HbA1c, and other markers related to insulin resistance, cholesterol, inflammation, body weight, and cardiovascular risk. These measures will be taken at baseline, day 42, and day 84. Participants will complete questionnaires and diaries and attend clinic visits to monitor their progress and safety throughout the trial, which starts in February 2026 and ends in September 2026.

A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes